Pharmaceutical composition and method for treating retinal neurodegeneration
AssigneeMetabolic Therapy Inc.
InventorKENNETH O. RUSSELL
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition useful for preventing and treating retinal neurodegeneration related diseases comprising chromium chloride and magnesium sulfate, thickening agent, penetration enhancer, and pharmaceutical acceptable carrier, diluent or excipient. Further disclosed is a method for treating and preventing retinal neurodegeneration related diseases utilizing the composition.
Claims20
A composition comprising:
- (a) about 0.002% to about 0.01% chromic chloride weight of the composition;
- (b) about 5% to about 25% magnesium sulfate weight of the composition;
- (c) about 75% to about 95% ethanol;
- (d) about 0.2% to about 3% isopropyl myristate;
- and
- (e) about 0.1% to about 6% of a thickening agent,
- wherein the percentages of components are weight to weight of the composition.
A unit dose packet comprising inner and outer surface, and a pharmaceutical composition inside the packet, the composition consisting essentially of:
- (a) about 0.002% to about 0.01% chromium chloride weight of the composition;
- (b) about 5% to about 25% magnesium sulfate weight of the composition;
- (c) about 75% to about 95% ethanol;
- (d) about 0.2% to about 3% isopropyl myristate;
- and
- (e) about 0.1% to about 6% of a thickening agent,
- wherein the percentages of components are weight to weight of the composition.
The packet of claim 7, wherein the composition weighs about 10.0 grams to 20.0 grams.
A method for topically administering the chromium chloride to a human subject in need thereof, the method comprising:
- a. providing a pharmaceutical composition consisting essentially of:
- (i) about 0.002% to about 0.01% chromium chloride weight of the composition;
- (ii) about 5% to about 25% magnesium sulfate weight of the composition;
- (iii) about 75% to about 95% ethanol;
- (iv) about 0.2% to about 3% isopropyl myristate;
- and
- (v) about 0.1% to about 6% of a thickening agent,
- (vi) wherein the percentages of components are weight to weight of the composition.
- b. applying a daily dose of the composition to skin of the subject in an amount sufficient for the chromium chloride to reach the bloodstream of the subject within at least about 48 hours of daily dosing of the composition.
The method of claim 15, wherein the chromium chloride is present in a concentration of about 0.005% weight to weight of the composition.
Dependencies are inferred from the claim text.